Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | TLR2 | O60603 | 3/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28624889 | 1.00 | KMT2A (0.49) | KMT2AMDM2IDO1PTPN1TLR2 | |
| SCHEMBL28627067 | 1.00 | KMT2A (0.49) | KMT2AMDM2IDO1PTPN1TLR2 | |
| SCHEMBL29586109 | 1.00 | KMT2A (0.49) | KMT2AMDM2IDO1PTPN1TLR2 | |
| SCHEMBL29989986 | 0.91 | KMT2A (0.52) | KMT2AMDM2PTPN1TLR2CASP3 | |
| SCHEMBL5323666 | 0.91 | KMT2A (0.52) | KMT2AMDM2PTPN1TLR2CASP3 | |
| SCHEMBL29792137 | 0.91 | KMT2A (0.52) | KMT2AMDM2PTPN1TLR2CASP3 | |
| SCHEMBL29350883 | 0.91 | KMT2A (0.52) | KMT2AMDM2PTPN1TLR2CASP3 | |
| SCHEMBL1709129 | 0.91 | KMT2A (0.52) | KMT2AMDM2PTPN1TLR2CASP3 | |
| SCHEMBL30074491 | 0.91 | KMT2A (0.52) | KMT2AMDM2PTPN1TLR2CASP3 | |
| SCHEMBL29591196 | 0.91 | KMT2A (0.52) | KMT2AMDM2PTPN1TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380605-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| CN-113286617-A | Pyrrolobenzodiazepine conjugates | 免疫医疗有限公司 | 2021-08-20 | — | — | CN | disclosed |
| US-20200407712-A1 | ARRAY-BASED CYCLIC PEPTIDE LIBRARIES | Cowper Sciences Inc. | 2020-12-31 | — | — | US | disclosed |
| EP-3749676-A1 | ARRAY-BASED CYCLIC PEPTIDE LIBRARIES | Healthtell Inc. (US) | 2020-12-16 | — | — | EP | disclosed |
| WO-2020079229-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2020-04-23 | — | — | WO | disclosed |
| WO-2019157362-A1 | ARRAY-BASED CYCLIC PEPTIDE LIBRARIES | HEALTHTELL INC. (US) | 2019-08-15 | — | — | WO | disclosed |
| US-5721210-A | OLIGOPEPTIDES AS ANTIINFLAMMATORY AGENTS OR INTEGRIN RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 1998-02-24 | — | — | US | disclosed |
| EP-0677060-A1 | PEPTIDE INHIBITORS OF CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994015958-A2 | PEPTIDE INHIBITORS OF CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1994-07-21 | — | — | WO | disclosed |
| EP-0538399-A4 | — | — | 1994-05-04 | — | — | EP | disclosed |
| EP-0538399-A1 | CYCLIC CELL ADHESION MODULATION COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 1993-04-28 | — | — | EP | disclosed |
| US-5192746-A | Cyclized integrin receptor antagonist compounds including adhesion to fibronectins, oligopeptides | TANABE SEIYAKU CO., LTD. (JP) | 1993-03-09 | — | — | US | disclosed |
| WO-1992000995-A1 | CYCLIC CELL ADHESION MODULATION COMPOUNDS | TANABE SEIYAKU CO. LTD. (JP) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380605-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | PRLHR, GLRA1, CXCR1 | KMT2A 1835/4885MDM2 3118/4885IDO1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.